Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Notified -
Globe Newswire19-02-2025, 19:05
Workplace Options Unveils Comprehensive & Compassionate Return-to-Work Program for Cancer Survivors 24-01-2025, 00:40